Stroke Prevention in Philadelphia: What the 2024 Guideline Actually Changes

How much of stroke is actually preventable?

The honest answer is: most of it. Modeling studies estimate that combining a Mediterranean-style diet, regular physical activity, smoking avoidance, blood pressure control, statin therapy, and antiplatelet or anticoagulant therapy when indicated can produce roughly an 80% cumulative reduction in recurrent vascular events.¹ The numbers for primary prevention are similar. The framework cardiologists and neurologists organize this around is the American Heart Association's Life's Essential 8: healthy diet, physical activity, weight management, healthy sleep, tobacco avoidance, and control of cholesterol, blood glucose, and blood pressure.² Stroke prevention is largely cardiometabolic prevention, with a few stroke-specific layers on top (atrial fibrillation screening, carotid disease, PFO). In Philadelphia, where roughly one in three adults has hypertension and rates are meaningfully higher in Black and lower-income neighborhoods, the prevention math weighs even heavier on blood pressure than the national averages suggest.

What does the 2024 guideline really change?

The 2024 AHA/ASA Primary Prevention Guideline updates the 2014 version in seven major ways:²³

1. Lower blood pressure target (<130/80) is a Class 1 recommendation for adults at higher ASCVD risk.
2. Mediterranean diet earns a Class 1 recommendation for those at intermediate-to-high cardiovascular risk.
3. GLP-1 receptor agonists are now Class 1A in type 2 diabetes with high cardiovascular risk or established disease.
4. Aspirin is downgraded to Class 2b for primary prevention, and Class 3 (harm) in adults over 70 without ASCVD or in those with CKD.
5. Sex-specific risk factor screening (preeclampsia history, early menopause, endometriosis) is a new Class 1 recommendation.
6. Potassium-enriched salt substitution (75% NaCl / 25% KCl) is a Class 2a recommendation.
7. Colchicine receives discussion as an anti-inflammatory option, primarily in patients with established coronary disease.

Everything below is how I work each of these into primary care.

Blood pressure: what's the real target, and what gets you there?

Hypertension is the single most impactful modifiable risk factor for stroke. Every 10 mmHg reduction in systolic blood pressure reduces stroke risk by about 41%.⁴ That is not a typo. There is no other lever in primary prevention that moves the needle this much. The 2024 guideline targets <130/80 mmHg in adults at elevated ASCVD risk. The trials behind that target:

• SPRINT showed that intensive treatment to a systolic of <120 reduced cardiovascular events compared to <140.
• STEP in elderly hypertensives showed a 33% lower incident stroke risk with a target of <130 vs. <150.
• ACCORD BP in diabetics showed a 41% lower stroke risk with <120 vs. <140 (secondary outcome).³

In practice:

• Most patients need two or more medications to reach goal. One agent is rarely enough.
• All major drug classes reduce stroke risk except alpha-blockers. ACE inhibitors and ARBs have particular benefit for stroke.⁵
• The reading that matters is the home reading, taken correctly: seated, feet flat, arm supported, two readings a minute apart, after five minutes of rest. Cuff blood pressure in a clinic with white coats and traffic noise routinely overestimates by 5-15 mmHg.

If you have a smart cuff at home, the cadence I ask for is two readings, twice a day, for a week, then send me the average. That gives a far better signal than any single office reading.

What does the Mediterranean diet actually do for stroke?

The PREDIMED trial is the centerpiece. It randomized 7,447 adults at high cardiovascular risk to a Mediterranean diet (supplemented with extra-virgin olive oil or nuts) vs. a low-fat control diet. Over a median 4.8 years of follow-up, the Mediterranean group had a 42% relative reduction in stroke (HR 0.58, 95% CI 0.42-0.82).⁶ In a secondary analysis, the highest quintile of Mediterranean diet adherence was associated with a 74% lower stroke risk vs. the lowest quintile.⁷ The practical version of "Mediterranean":

• Olive oil as the primary fat. Two to four tablespoons a day in PREDIMED.
• A handful of nuts most days (walnuts, almonds, hazelnuts in the trial).
• Fish at least twice a week, ideally fatty fish (salmon, sardines, mackerel).
• Beans and lentils most days.
• Vegetables and fruit at most meals.
• Whole grains, not refined.
• Modest wine, if you already drink. Don't start.
• Red and processed meat as the exception, not the rule.

The low-fat diet did not reduce stroke risk meaningfully in PREDIMED.⁶ DASH is excellent for blood pressure but does not have stroke as a primary endpoint, which is why the 2024 guideline specifically points at Mediterranean. A useful Philly note: the produce and seafood at Reading Terminal, the Italian Market, and the Asian markets along Washington Avenue make this diet easier here than in most of the country. Cherry tomatoes, fresh basil, anchovies, and good olive oil are not a special-occasion grocery run. Potassium salt substitution (75% sodium chloride / 25% potassium chloride) earned a Class 2a recommendation based on the SSaSS trial, which showed a 22% relative reduction in stroke in adults over 60 with elevated blood pressure.³ This is cheap, easy, and underused. The caveat: not for patients with advanced CKD or on potassium-sparing diuretics or ACE inhibitors / ARBs without a discussion about hyperkalemia risk.

What are the under-recognized nutritional gaps?

The Mediterranean pattern captures most of the gains, but a few specific nutrient gaps and dietary patterns deserve their own callout because they show up in patients who otherwise look like they are eating reasonably.

• Magnesium. Each 100 mg/day increase in magnesium intake is associated with a 13% lower stroke risk.⁵² Mendelian randomization supports a causal relationship for cardioembolic stroke, likely mediated through magnesium's anti-arrhythmic effect and reduced atrial fibrillation risk.⁵³ A clinically useful tool is the Magnesium Depletion Score (built from PPI use, diuretic use, kidney function, and alcohol intake): patients in the high-depletion category had nearly double the odds of stroke (OR 1.96).⁵⁴ Magnesium also lowers blood pressure in RCTs, with a meta-analysis of 38 trials showing SBP −2.81 / DBP −2.05 mmHg overall, but a much larger effect in hypertensives on medication (SBP −7.68) and in those with documented hypomagnesemia (SBP −5.97).⁶⁷ It also improves flow-mediated dilation by roughly 3% and, in thiazide-treated hypertensive women, 600 mg/day of magnesium chelate over 6 months prevented carotid intima-media thickness progression.⁶⁸ The average American consumes roughly 270 mg/day vs. an RDA of 320-420 mg. Food sources first: pumpkin seeds, dark leafy greens, almonds, black beans, dark chocolate, fatty fish. When supplementing, chelated forms (glycinate, taurate, threonate) are better tolerated and better absorbed than magnesium oxide, which is mostly a laxative. Caution in advanced CKD. (One thing magnesium does not do well: IV magnesium for acute stroke. FAST-MAG and seven other RCTs showed no functional or mortality benefit.⁶⁹ The lever is dietary intake over decades, not rescue therapy at the bedside.) Full forms, dosing, and interactions in the magnesium glycinate guide.
• Potassium, independent of sodium. Each 1,000 mg/day increase is associated with a 9% lower stroke risk, and a combined high-magnesium / high-potassium / high-calcium dietary score (highest quintile) was associated with a 28% lower stroke risk.⁵² Forms, food sources, and the salt-substitute strategy are in the potassium guide.
• Fiber. Each 10 g/day increase in dietary fiber was associated with a 23% lower ischemic stroke risk in the EPIC cohort (418,329 participants).⁵⁵ The typical American eats about 15 g/day; the target is 25-35 g/day. Beans, oats, berries, vegetables, and whole grains do the work.
• Ultra-processed foods (UPFs). High UPF intake is associated with a 14% increased risk of cerebrovascular disease or mortality, with a larger effect signal in Black participants in the REGARDS cohort.⁵⁶⁵⁷ The Southern dietary pattern (added fats, fried food, processed meats, sugar-sweetened beverages) was associated with a 39% increased stroke risk in REGARDS.⁵⁸ In Philadelphia, where takeout, deli food, and quick-service dominate large sections of the food landscape, swapping UPF for whole-food alternatives is one of the higher-leverage shifts available.

The headline: most nutrition gaps in the patients we see are not exotic - they are too much sodium, not enough magnesium and potassium, not enough fiber, and too much ultra-processed food. The Mediterranean framework fixes most of these at once.

When does a GLP-1 receptor agonist make sense for stroke prevention?

The most consequential addition to the 2024 guideline. For patients with type 2 diabetes, HbA1c ≥7%, and high ASCVD risk or established cardiovascular disease, GLP-1 receptor agonists earned a Class 1A recommendation for primary stroke prevention.⁸ Meta-analytic evidence across 28 RCTs (n = 74,148):

• 17% reduction in adverse cerebrovascular outcomes (RR 0.83, 95% CI 0.76-0.91)
• 27% reduction in ischemic stroke (RR 0.73, 95% CI 0.60-0.89)
• Benefits significant for dulaglutide, semaglutide (injectable and oral), greater in patients with shorter diabetes duration and preserved kidney function.⁹

GLP-1 RAs reduce stroke more effectively than SGLT2 inhibitors in head-to-head meta-analyses (RR 0.77, 95% CI 0.62-0.95). SGLT2 inhibitors and DPP4 inhibitors do not significantly reduce stroke risk.¹⁰ Emerging data from the SELECT trial suggests cardiovascular benefits may extend to overweight and obese patients without diabetes, though the 2024 guideline does not yet recommend GLP-1 RAs for stroke prevention outside of diabetes.¹¹ Watch this space. What this means in practice: if you have type 2 diabetes and any of the following (established CHD, prior stroke or TIA, peripheral arterial disease, multivessel disease on imaging, or a high enough 10-year ASCVD risk score), the GLP-1 RA is not optional add-on therapy. It is preventive cardiology.

Where do fasting insulin, HOMA-IR, and the TyG index fit?

This is one of the places where I think the guideline is meaningfully under-stating the lever. Insulin resistance sits upstream of nearly every modifiable stroke risk factor: hypertension, atherogenic dyslipidemia, atrial fibrillation risk, endothelial dysfunction, and the prothrombotic state.²⁴ The 2024 guideline gestures at it through diabetes management, but the honest framing is that catching insulin resistance years before HbA1c rises is one of the highest-leverage things we do in preventive care. The epidemiology is genuinely mixed. A meta-analysis of seven prospective studies found that the highest vs. lowest quantile of fasting insulin was not significantly associated with stroke (pooled RR 1.18, 95% CI 0.87-1.60), and a separate meta-analysis of HOMA-IR found a similar non-significant pooled RR of 1.29.²⁵²⁶ The adjustment is the problem: hypertension, dyslipidemia, and inflammation are all downstream of insulin resistance, so adjusting for them washes out the very effect you are trying to measure. The Mendelian randomization data are cleaner. A genetic predisposition to insulin resistance (a 1-log increment in fasting insulin) was associated with a 33% higher risk of ischemic stroke (OR 1.33, 95% CI 1.13-1.57), with particularly strong effects on large-artery stroke (OR 1.60) and small-vessel stroke (OR 1.63).²⁷ Because Mendelian randomization is not confounded by lifestyle or downstream risk factors, this is the closest the field gets to causal evidence. What I actually measure:

• Fasting insulin alongside fasting glucose. We aim under 5 µIU/mL and get concerned over 10.
• HOMA-IR, calculated as (fasting insulin × fasting glucose) / 405. Optimal under 1.0; insulin resistance defined as ≥2.5; the IRIS trial used ≥3.0 as its entry threshold.
• TyG index, calculated as ln(fasting triglycerides × fasting glucose / 2). Pulled from a standard lipid panel and basic metabolic panel, no special order required. A meta-analysis of 11 cohorts (5.7 million subjects, 95,490 strokes) showed the highest vs. lowest TyG was associated with a 27% increased stroke risk, with a stronger signal for ischemic stroke (RR 1.48).²⁸
• hs-CRP, because chronic inflammation partially mediates the IR-stroke link.

When to measure:

• In primary prevention: I order fasting insulin and HOMA-IR when there are clinical features of insulin resistance (central adiposity, acanthosis nigricans, hypertension, metabolic syndrome components, PCOS, NAFLD) even if HbA1c is under 5.7%. The PESA study found that among individuals with normal HbA1c, a HOMA-IR ≥3 was independently associated with subclinical atherosclerosis (OR 1.74 for coronary artery calcium > 0).³² The signal is amplified in prediabetes: a Chinese cohort of 111,576 adults found HOMA-IR strongly predicted CVD in prediabetes (HR 1.23) but not in normoglycemia (HR 1.03).³³
• After a stroke or TIA: measure fasting insulin and glucose at least 14 days after the index event to calculate HOMA-IR. Insulin sensitivity is transiently impaired in the acute post-stroke period, and an earlier draw will overestimate IR.²⁹ The IRIS trial used a threshold of ≥3.0, which captures roughly the top quartile of nondiabetics.

A useful ARIC Study finding for stratification: the fasting-insulin-to-stroke association was significantly stronger in women, in whites, and in those without hypertension (each p-interaction < 0.05).³¹ The reading: in patients whose blood pressure is well-controlled, fasting insulin may be a more informative marginal signal than people give it credit for. The therapeutic payoff is real. The IRIS trial (Insulin Resistance Intervention After Stroke) randomized 3,876 nondiabetic patients with a recent ischemic stroke or TIA and HOMA-IR ≥3.0 to pioglitazone (target 45 mg) vs. placebo. Over a median 4.8 years:²⁹

• 24% reduction in the composite of stroke or MI (HR 0.76, 95% CI 0.62-0.93)
• 28% reduction in ischemic stroke specifically (HR 0.72)
• 52% reduction in new-onset diabetes (HR 0.48)
• In the prediabetes subgroup with good adherence, stroke/MI fell by 43%.³⁰

The trade-offs are real: weight gain, fluid retention, and increased fracture risk. Lower doses (15-30 mg) mitigate some side effects but may give up some of the benefit. The 2026 ADA Standards now formally endorse pioglitazone for stroke or MI risk reduction in post-stroke patients with insulin resistance or prediabetes (Grade A evidence). For primary stroke prevention, pioglitazone is not in the guideline. The lever for primary prevention remains lifestyle (Mediterranean diet, weight loss, resistance and zone-2 cardio, sleep, alcohol), metformin in some patients, and GLP-1 RAs in diabetics with cardiovascular risk. But measuring fasting insulin and HOMA-IR is how we catch this years before HbA1c moves - and that earlier catch is when lifestyle is at its most leveraged.

What does VO₂max actually do for stroke risk?

If insulin resistance is the upstream metabolic lever, cardiorespiratory fitness (CRF) is the upstream functional lever, and it deserves its own section. CRF is one of the strongest independent predictors of stroke risk we have, and unlike most predictors it is genuinely modifiable through structured training. The headline numbers:

• A dose-response meta-analysis of 14 cohort studies (1.4 million participants) found that every 5-MET increment in CRF was associated with a 15% lower stroke risk (RR 0.85, 95% CI 0.79-0.91), with reductions for both ischemic (29%) and hemorrhagic stroke (31%).⁴¹
• In the Kuopio Ischemic Heart Disease Study, men with low VO₂max (< 25.2 mL/kg/min) had a 3.2-fold higher risk of any stroke vs. fit men (> 35.3 mL/kg/min), comparable in predictive value to systolic blood pressure, smoking, and LDL.⁴²
• In the Henry Ford FIT Project (67,550 patients), achieving ≥12 METs was associated with a 58% lower stroke risk vs. the least-fit group. Critically, each 1-MET improvement between serial exercise tests was independently associated with a 9% lower ischemic stroke risk (HR 0.91, 95% CI 0.88-0.94) - meaning the trajectory matters as much as the starting point.⁴³
• A Norwegian cohort followed for 7 years showed that men who improved their fitness had a 60% lower stroke risk (HR 0.40), and men who lost fitness had a 2.35-fold higher risk.⁴⁴
• The Cooper Center Longitudinal Study (19,815 individuals) showed midlife CRF in the top two quintiles was associated with 37-39% lower stroke risk after age 65, and this association held even after adjusting for incident hypertension, diabetes, and atrial fibrillation - meaning CRF in midlife protects against stroke partly through pathways the traditional risk factors miss.⁷⁰

The AHA has formally argued for treating CRF as a clinical vital sign alongside blood pressure and BMI.⁴⁵ CRF outperforms the Framingham Risk Score and the ACC/AHA Pooled Cohort Equations for predicting cardiovascular and all-cause mortality, with a net reclassification improvement of 12-13% when added to standard scores. It belongs on the dashboard. The dose-response has two practical implications most patients underweight:

1. The largest marginal benefit happens moving from inactive to even modestly active. A meta-analysis of 752,050 participants showed even below-target leisure-time activity reduced stroke risk by 18%, and ideal-target activity reduced it by 29%.⁴⁶ A 2026 network meta-analysis of 50 RCTs found that structured exercise alone reduced stroke incidence by 60%.⁴⁷
2. There is an "asymptote of gain" for stroke specifically. In the Aerobics Center Longitudinal Study, the most fit men (13.1 METs) had a 68% lower stroke-death risk vs. the least fit (8.5 METs), but moderate fitness (10.5 METs) already produced 63% of that benefit. For stroke, you do not need to be elite - you need to clear the moderate-fitness threshold. For all-cause mortality, however, no upper threshold of harm exists; benefit continues to accrue even at 14+ METs.⁷¹

The 2024 AHA/ASA target: 150 minutes/week of moderate-intensity aerobic activity or 75 minutes/week of vigorous activity, plus strength training at least two days/week. Sedentary time is an independent risk multiplier - each hour beyond about 6.5 hours/day of sedentary time raises stroke risk by roughly 6%, on top of whatever you do at the gym.⁸ What this looks like in practice in Philadelphia: If you are starting from sedentary, do not skip the ramp-up. The 150-minute target is a steady-state goal, not a week-1 prescription, and pushing too hard too fast is the most common reason people drop out. A useful analogy: the cleanest evidence on how to safely re-condition someone starting from zero comes from the cardiac- and stroke-rehab literature, where investigators had to work out how to get profoundly deconditioned patients moving without triggering an event. The principles transfer directly to a healthy 35- or 45-year-old who has been sedentary for five years. The framework: multiple shorter bouts (5-15 minutes spread through the day) produce a real training effect at intensities as low as 30-40% of heart-rate reserve in unfit adults. A reasonable 8-12 week ramp - start with two 10-15 minute walks per day at RPE 11-12 (Borg, "feels like light exercise"), add one slightly harder session per week, and build toward the steady-state target by month three. The trajectory of CRF is what predicts stroke, not the snapshot. The job is to get on the curve.

• Zone 2 cardio, 3-4 days a week, 30-45 minutes per session - a brisk walk on Forbidden Drive, a steady bike ride along the Schuylkill River Trail, an easy jog around Boathouse Row. Zone 2 is the heart-rate band where you can hold a conversation but it's mildly inconvenient (roughly 60-70% of max heart rate).
• One zone-5 session per week - a higher-intensity interval session (4x4 minutes hard, 3 minutes easy is the Norwegian protocol that works for most people). This is what actually moves VO₂max.
• Two strength sessions per week, hitting major movement patterns (squat, hinge, press, pull, carry).
• Daily walking to keep sedentary hours under 6-7 - the easiest version is a 10-minute walk after each meal, which also helps postprandial glucose.

If you can do one thing: measure CRF and track it. A formal CPET in a lab gives a true VO₂max; a treadmill-derived MET estimate at a stress test is a reasonable surrogate; a Garmin or Apple Watch-estimated VO₂max is imperfect but useful for trend. The trajectory of CRF over time is what predicts stroke, more than any single snapshot. One technical note for anyone on a beta-blocker (commonly used for BP, AF, or migraine prevention): heart-rate-based training zones become unreliable, because the beta-blocker blunts the HR-to-workload relationship. Studies show percentage-of-VO₂peak prescriptions misclassify intensity in 67-74% of beta-blocker patients. The fix is to anchor intensity to perceived exertion (Borg 11-12 for zone 2, 15-17 for hard intervals) or the talk test (conversational = zone 2; gasping = hard). Or, if a formal CPET is available, intensity targets can be set at the ventilatory threshold, which is independent of heart rate.

What's the right approach to lipids for stroke prevention?

Statins reduce first stroke risk by about 19-22% in high-cardiovascular-risk adults.⁴ Atorvastatin and rosuvastatin are the most potent for cardiovascular event reduction. The 2026 ACC/AHA Dyslipidemia Guideline supports a statin first, then ezetimibe, then PCSK9 inhibitor escalation if LDL-C targets are not met in high-risk primary prevention patients.¹²

• PCSK9 inhibitors reduce stroke odds by 23% when added to statin (OR 0.77, 95% CI 0.67-0.89) across 20 RCTs, though no trial has tested them in pure primary stroke prevention yet.⁴
• Bempedoic acid showed a favorable but non-significant trend for stroke in CLEAR Outcomes (HR 0.76, 95% CI 0.46-1.26).²
• High-intensity statin therapy (atorvastatin 80 mg or equivalent) is the standard for non-embolic ischemic stroke with LDL > 100, with the LDL target of <70 mg/dL for established atherosclerosis.¹³

A separate but related lever: Lp(a) testing. About one in five adults carry elevated Lp(a), which independently raises stroke risk and runs in families. We test once and use the result to calibrate how aggressive to be on the modifiable risk factors. Full write-up: Lp(a): The Genetic Heart Risk.

What about aspirin?

Probably the most important shift in the 2024 guideline. Aspirin for primary prevention has been downgraded:

• Class 2b (uncertain benefit) in individuals without prior cardiovascular disease.
• Class 3 (harm) in adults aged 70 and older without established ASCVD.
• Class 3 (harm) in patients with chronic kidney disease without ASCVD.³

If you have been on a daily 81 mg "for your heart" without a clear cardiovascular indication, this is worth a conversation. The bleeding risk - particularly intracranial - was underweighted in the older guidelines. The trial that crystallized the modern view is ASCEND (n = 15,480 diabetics, no prior cardiovascular disease). Aspirin reduced serious vascular events by a relative 12% (8.5% vs. 9.6%) but caused a relative 29% increase in major bleeding (4.1% vs. 3.2%), mostly gastrointestinal. Absolute benefit and absolute harm were roughly a wash.³⁴ The estimated number needed to treat to prevent one vascular event in modern primary prevention is around 1,745 - which is to say, the marginal benefit is small enough that any meaningful bleeding risk tips the calculation. ASCEND is the cleanest example of where evidence-based preventive primary care actually thrives. The trial enrolled the exact population we are usually asked about (high-risk diabetics, no prior cardiovascular event), and gave us absolute event rates and absolute bleeding rates that translate directly to the individual in the room. No extrapolation needed. The clinical work is then matching that population-level answer to a specific patient's bleeding history, age, kidney function, and competing priorities. That match is the value of a longitudinal relationship: trial data is a starting point, not a verdict. A practical decision filter: aspirin is essentially contraindicated for primary prevention if any of the following apply: age ≥70 without ASCVD, chronic kidney disease without ASCVD, prior peptic ulcer disease or GI bleed, concurrent anticoagulation, active or recent intracranial bleeding, thrombocytopenia, or any chronic NSAID requirement that cannot be deprescribed. The 2019 ACC/AHA Primary Prevention Guideline gives a Class III (Harm) recommendation for primary prevention aspirin in any of these populations.³⁵ A new wrinkle: ticagrelor 60 mg added to aspirin beyond 12 months (up to 3 years) is a Class 2b option for stroke prevention in patients with stable coronary heart disease and low bleeding risk, based on the PEGASUS-TIMI 54 trial (15% relative stroke reduction).³ For secondary prevention after ischemic stroke or TIA, antiplatelet therapy stays. Short-term dual antiplatelet therapy (aspirin + clopidogrel) for 21-90 days is recommended for minor stroke or high-risk TIA presenting within 24 hours. Long-term DAPT is not recommended due to bleeding.¹⁴

Atrial fibrillation: the biggest single-intervention win

AF-related anticoagulation produces the largest single-intervention risk reduction for stroke: about 64% relative risk reduction (95% CI 49-74%).⁴ Nothing else comes close on a single intervention basis. The practical playbook:

• Screen for AF in adults at risk, particularly after age 65 or in the workup of cryptogenic stroke. Apple Watches and consumer wearables have made opportunistic screening much easier; abnormal rhythm notifications are worth bringing in for confirmation.
• DOACs are preferred over warfarin for non-valvular AF: 19% reduction in stroke or systemic embolism and 51% reduction in hemorrhagic stroke compared to warfarin.¹⁵
• Apixaban is the preferred DOAC in patients with a history of GI bleeding. Population-based studies show significantly lower GI bleeding with apixaban vs. rivaroxaban (HR 0.33-0.54) and dabigatran (HR 0.39-0.46), and apixaban was the only DOAC that did not significantly increase GI bleeding vs. warfarin in its pivotal trial.³⁶
• Threshold for anticoagulation is generally an annual stroke risk of ≥2%, which translates to CHA₂DS₂-VASc ≥2 in men and ≥3 in women.²¹⁶
• Aspirin is not adequate for stroke prevention in AF and should not substitute for anticoagulation.¹⁷
• Left atrial appendage occlusion (LAAO) is an option in high-bleeding-risk AF patients who have relative or absolute contraindications to long-term anticoagulation, per the 2023 ACC/AHA/ACCP/HRS guideline.³⁷
• After a cryptogenic stroke, extended cardiac monitoring (loop recorder, extended Holter) is recommended when no other cause is identified.¹⁴

What's new for women?

The 2024 guideline introduced Class 1 recommendations for screening women for sex-specific stroke risk enhancers, a meaningful departure from 2014.¹⁸¹⁹ The list:

• Hypertensive disorders of pregnancy (preeclampsia, eclampsia, gestational hypertension): associated with an 80% increased lifetime risk of ischemic stroke (RR 1.80, 95% CI 1.49-2.18).²⁰
• Premature ovarian failure (<40 years) and early-onset menopause (<45 years): associated with increased stroke risk.
• Endometriosis: newly recognized as a stroke risk enhancer.
• Preterm delivery and stillbirth: associated with 62% and 86% increased stroke risk, respectively.²⁰
• Combined hormonal contraceptives: independent risk factor, particularly in women aged 30-49.²¹
• Late menopause (≥55 years): associated with increased hemorrhagic stroke risk.

Midlife - roughly 40 to 65 - is the critical window for women's stroke and dementia prevention. Hormonal, metabolic, and vascular changes converge in that decade, and the prevention math during it is unusually leveraged.¹⁹ If you had preeclampsia 20 years ago and no one has revisited cardiovascular screening since, that is worth fixing.

Should I be checking my carotids?

Routine screening of asymptomatic adults for carotid stenosis is not recommended by the USPSTF, because the harms of intervening on incidental moderate stenosis often outweigh the benefits. There are exceptions:

• Severe symptomatic ipsilateral stenosis after an ischemic stroke or TIA: carotid endarterectomy or stenting is indicated relatively early after the event.¹⁴
• Multivessel atherosclerosis on imaging done for another indication often triggers carotid imaging.

What I do look at, when the patient is interested and the risk profile supports it, is a coronary calcium score (CAC) or, in higher-risk patients, Cleerly AI plaque analysis. The plaque you find in the coronaries is a strong proxy for vascular age generally, and shifts the calculus on statin intensity, BP targets, and aspirin.

What about secondary prevention after a stroke or TIA?

After an ischemic event, the 2021 AHA/ASA Secondary Prevention Guideline tailors strategy to the stroke subtype.¹⁴ The high-level moves:

• Blood pressure target <130/80 reduces recurrent stroke risk by about 20% vs. less strict targets.²² Preferred agents: thiazides, ACE inhibitors, ARBs.
• High-intensity statin for non-embolic stroke with LDL > 100, escalating with ezetimibe or PCSK9 inhibitor to LDL < 70 mg/dL.¹³
• HbA1c ≤7% with metformin plus a GLP-1 RA or SGLT2 inhibitor.¹³
• DOAC for non-valvular AF, plus cardiac monitoring for occult AF when no other cause is identified.
• Pioglitazone can be considered in nondiabetic patients with HOMA-IR ≥3.0 or prediabetes, based on the IRIS trial (24% reduction in stroke/MI). Weigh against weight gain and fracture risk.
• PFO closure is reasonable in patients aged 18-60 with a nonlacunar stroke, no other identified cause, and high-risk PFO features.¹⁴
• Embolic stroke of undetermined source (ESUS) should not be empirically anticoagulated. NAVIGATE-ESUS and RE-SPECT ESUS showed no benefit of rivaroxaban or dabigatran over aspirin.¹⁴
• Lifestyle: Mediterranean diet, sodium reduction, moderate physical activity, smoking cessation, weight management.

What about supplements?

This section is short because the evidence is mostly negative, and one popular supplement actually appears to increase stroke risk. What may help:

• Folic acid is the only supplement with convincing RCT evidence for stroke prevention. A meta-analysis of 7 RCTs (24,525 participants) showed a 21% relative reduction in stroke risk (RR 0.79; NNT 148).⁴⁸ The catch: most of the signal comes from the CSPPT trial in China, where wheat flour is not folate-fortified. In the US, where flour has been fortified since 1998, the marginal benefit of additional folic acid is much smaller in the general population. Where it does seem to help in the US: patients with elevated homocysteine, MTHFR polymorphisms, or documented folate deficiency. Hyperhomocysteinemia is present in roughly 19% of stroke patients, and ~10-19% of stroke / TIA patients have metabolic B12 deficiency on careful testing - this is a missed opportunity that does not need to wait for a stroke to surface.⁷³ Our actual testing pattern (homocysteine, MMA, and MCV instead of serum B12 / folate, with treat-to-target thresholds of tHcy < 7 and MCV < 86) lives in the B-complex guide.
• B-complex vitamins (folate + B6 + B12) reduced stroke risk by about 10% (RR 0.90) in a pooled analysis, again with most of the signal in non-fortified populations.⁴⁸
• Icosapent ethyl (Vascepa) - prescription, not a supplement - reduced stroke by 28% in REDUCE-IT (HR 0.72), but only in patients with established cardiovascular disease or diabetes already on a statin and with persistent hypertriglyceridemia.⁴⁹ This is not the same as over-the-counter fish oil.

What does not help, despite the marketing:

• Vitamin D alone showed no reduction in CVD events or stroke in the VITAL trial (n = 25,871; 2,000 IU/day vs. placebo, HR 0.97), even in participants with baseline 25(OH)D < 20 ng/mL.⁵⁰ UK Biobank observational data show severe deficiency (< 25 nmol/L) is associated with a 40% higher stroke risk, but Mendelian randomization does not support a causal link for stroke (unlike for dementia, where causality is confirmed).⁵⁹ Test, treat documented deficiency in a targeted way, do not supplement reflexively for stroke risk reduction alone. See the vitamin D3 guide for the full clinical workup.
• Marine omega-3 (1 g/day) showed no stroke benefit in VITAL.⁵⁰ The omega-3 story is nuanced and worth a longer look (see below).
• Multivitamins, vitamin C, vitamin E, selenium, antioxidant combinations - no stroke benefit in RCTs, and antioxidant mixtures showed a marginally increased stroke risk.
• Niacin - no stroke benefit, and a marginally significant increase in all-cause mortality when added to a statin.

What appears to cause harm:

• Calcium supplements, with or without vitamin D, were associated with an increased stroke risk (RR 1.17, 95% CI 1.06-1.30) across 7 RCTs.⁵¹ The mechanism is plausible: supplemental calcium creates rapid serum-calcium spikes that dietary calcium does not, which appears to accelerate vascular calcification. In practice, I have seen ischemic strokes in patients as young as their early 50s who were on long-term calcium supplements without a clear indication.

The clinical version: dietary calcium is fine and important; supplemental calcium without a documented deficiency or osteoporosis indication is not. For most adults, 1,000-1,200 mg/day from food (dairy, leafy greens, fortified plant milks, sardines, tofu) is the right approach. If supplementation is clinically necessary, split doses (≤500 mg at a time) and pair with vitamin D and weight-bearing exercise. We revisit this at every membership review, particularly in postmenopausal women who were started on calcium by a previous clinician. The full calcium-and-cardiovascular picture lives in the calcium guide.

What about the Omega-3 Index?

The omega-3 story is one of the cleanest examples of why biomarker-guided prevention beats blanket supplementation. The Omega-3 Index (O3I) is the percentage of EPA + DHA in the red blood cell membrane, and it tracks long-term tissue omega-3 status better than any single plasma measurement.⁶⁰ Risk zones:

• High risk: O3I < 4%
• Intermediate: 4-8%
• Target: > 8% (8-11% is the optimal range)

An O3I > 8% has been associated with roughly a 90% lower risk of sudden cardiac death vs. < 4%, and a 1-SD increase in O3I is associated with a 15% lower CHD mortality (HR 0.85).⁶¹ In the Framingham Offspring cohort, the highest O3I quintile (> 6.8%) had 39% lower incident CVD and 34% lower all-cause mortality over 7.3 years.⁶² A 2024 analysis showed that adding the O3I to the Pooled Cohort Equations meaningfully improved 10-year ASCVD risk prediction.⁶³ For stroke specifically, the observational signal is real but smaller than for CHD. A pooled analysis of 29 prospective cohorts (183,291 participants, 10,561 strokes) showed that the highest vs. lowest quintile of EPA was associated with 17% lower total stroke (HR 0.83) and 18% lower ischemic stroke (HR 0.82).⁶⁴ The catch: RCT supplementation data are largely neutral for stroke. A Cochrane review of 31 trials found omega-3 supplementation made little or no difference (RR 1.02).⁶⁵ One important exception: EPA monotherapy (icosapent ethyl in REDUCE-IT) reduced non-fatal stroke by 29% (RR 0.71), while EPA+DHA combination products did not.⁴⁹ And high-dose omega-3 (> 1 g/day) increases atrial fibrillation risk (HR ~1.49), which could itself raise cardioembolic stroke risk.⁶⁶ The practical version:

• Fatty fish first - two to three servings per week of salmon, sardines, mackerel, anchovies, or trout will move the O3I more reliably than most over-the-counter capsules.
• Test the O3I if you are at elevated cardiovascular risk and the answer matters. Available through quest, labcorp, and direct-to-consumer panels.
• If the O3I is below target despite dietary effort, target the gap: high-EPA formulations (not mixed EPA+DHA tonics) get closer to the REDUCE-IT signal. Doses above 1 g/day need an explicit AF-risk conversation, particularly in older adults or anyone with palpitations.
• OTC fish oil bottle on the counter, dose unknown, brand unverified is the version that produces the negative RCT result. We do better than that.

A note on the guideline tension: the 2024 AHA/ASA Primary Prevention of Stroke Guideline assigned omega-3 supplementation a Class 3 (no benefit) recommendation, based on the body of trials that used ~1 g/day of mixed EPA+DHA without biomarker targeting. Our clinical view is that this null finding reflects product quality, dose, and protocol - not omega-3 efficacy. When we prescribe omega-3 for ASCVD and cerebrovascular risk reduction, we use Lovaza (Rx EPA+DHA) when insurance covers it, icosapent ethyl (Vascepa) at 4 g/day when the patient meets REDUCE-IT criteria, or specific clean third-party-tested EPA+DHA formulations at 2-3 g/day dosed to an O3I target. The omega-3 guide walks through this decision in full.

How we work this in primary care

Stroke prevention is not a single visit or a single number. It is the accumulation of small decisions, made consistently, over decades. In our membership model the practical version looks like this:

• Baseline visit maps the modifiable risk factors: home BP averages, ApoB, Lp(a), HbA1c, fasting insulin, fasting lipid panel, kidney function, body composition, sleep quality, alcohol, and (for women) reproductive history.
• A CAC score when appropriate, or Cleerly plaque imaging in higher-risk patients.
• A medication review that explicitly asks: are you on aspirin you should not be on, are you missing a GLP-1 RA you should be on, are you on a statin at the right intensity, is your blood pressure regimen actually getting you to <130/80.
• For women, an explicit reproductive and menopausal history with the 2024 risk enhancers in mind.
• For patients over 65 or with palpitations, opportunistic AF screening via wearable or office EKG.

This is where a longitudinal primary care relationship earns its keep. The 2024 guideline is a long list of tools, each with a benefit profile and a side-effect profile that depends on the patient in front of you. Pioglitazone helps if your HOMA-IR is high, but the fracture risk shifts the calculus if you also have osteoporosis. A GLP-1 RA is Class 1A in diabetes with cardiovascular risk, but a history of pancreatitis or medullary thyroid cancer changes the choice. Aspirin can save a life in established disease and end one in a patient with a prior GI bleed. Drawing the benefits from each tool while mitigating the risks - the work of fitting a guideline to a person rather than a person to a guideline - is exactly what a long-term primary care relationship makes possible. We have the time to do this carefully because the membership is built around it.

Key Takeaways

• About 80% of strokes are preventable with a coordinated cardiometabolic strategy.
• Blood pressure is the single most impactful lever. Target <130/80 in higher-risk adults; most people need two or more medications.
• Mediterranean diet has direct trial evidence for a ~42% relative stroke reduction. DASH lowers BP but does not have the same stroke endpoint data.
• Under-recognized nutrient gaps: magnesium (each 100 mg/day = 13% lower stroke; check Mg Depletion Score in patients on PPIs / diuretics), potassium independent of sodium, fiber (each 10 g/day = 23% lower ischemic stroke), and ultra-processed food load.
• Omega-3 Index > 8% is the target. Observational stroke data are favorable, RCT supplementation data are not - the resolution is fatty fish first, biomarker-guided supplementation second, and EPA-only formulations preferred when used.
• GLP-1 RAs are Class 1A in type 2 diabetes with cardiovascular risk and cut ischemic stroke risk by about 27%.
• Aspirin for primary prevention has been downgraded and is considered harmful in adults over 70 without established disease.
• AF anticoagulation is the single biggest stroke-prevention intervention, with a 64% relative risk reduction. DOACs over warfarin.
• Sex-specific screening (preeclampsia, early menopause, endometriosis, preterm delivery) is now a Class 1 recommendation.
• Insulin resistance is upstream of nearly every modifiable risk factor. Fasting insulin, HOMA-IR, and the TyG index catch it years before HbA1c moves. Pioglitazone has Grade A evidence for stroke or MI reduction in post-stroke patients with HOMA-IR ≥3.0.
• Cardiorespiratory fitness (VO₂max) is one of the strongest modifiable predictors of stroke. Each 1-MET improvement is worth ~9% lower ischemic stroke risk. Treat CRF as a clinical vital sign and track the trajectory.
• Most supplements do not prevent stroke. Folic acid is the lone exception (and mostly in non-fortified populations); calcium supplements without a clear indication are associated with increased stroke risk and should be stopped in most patients.
• Lp(a) testing identifies the 1 in 5 adults with an inherited stroke risk factor.
• Secondary prevention after stroke or TIA is subtype-specific and includes high-intensity statin, BP <130/80, anticoagulation if AF, PFO closure in selected patients, and a Mediterranean diet.

Scientific References

1. Bridgwood B, Lager KE, Mistri AK, et al. Interventions for improving modifiable risk factor control in the secondary prevention of stroke. Cochrane Database Syst Rev. 2018. 2. Bushnell C, Kernan WN, Sharrief AZ, et al. 2024 Guideline for the Primary Prevention of Stroke: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2024. 3. Razavi AC, Troy AL, Patel J, et al. Future of Stroke Prevention: 7 Updates in the 2024 AHA/ASA Primary Prevention of Stroke Guideline. JACC Adv. 2025. 4. Diener HC, Hankey GJ. Primary and Secondary Prevention of Ischemic Stroke and Cerebral Hemorrhage: JACC Focus Seminar. J Am Coll Cardiol. 2020. 5. Hilkens NA, Casolla B, Leung TW, de Leeuw FE. Stroke. Lancet. 2024. 6. Estruch R, Ros E, Salas-Salvadó J, et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts. N Engl J Med. 2018. 7. Castro-Barquero S, Rimm EB, Jovin TG, et al. Adherence to Different Dietary Patterns and Subsequent Risk of Total, Ischemic, and Hemorrhagic Stroke. Stroke. 2026. 8. Wilson LM, Anderson TS. Use and Eligibility for GLP-1 Receptor Agonist Treatment for Primary Prevention of Stroke. Neurology. 2025. 9. Banerjee M, Pal R, Mukhopadhyay S, Nair K. GLP-1 Receptor Agonists and Risk of Adverse Cerebrovascular Outcomes in Type 2 Diabetes: A Systematic Review and Meta-Analysis of RCTs. J Clin Endocrinol Metab. 2023. 10. Drake T, Landsteiner A, Langsetmo L, et al. Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Systematic Review and Network Meta-Analysis for the American College of Physicians. Ann Intern Med. 2024. 11. Hosseinpour A, Sood A, Kamalpour J, et al. GLP-1 Receptor Agonists and Major Adverse Cardiovascular Events in Patients With and Without Diabetes: A Meta-Analysis of RCTs. Clin Cardiol. 2024. 12. Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA Guideline on the Management of Dyslipidemia. J Am Coll Cardiol. 2026. 13. Ford B, Peela S, Roberts C. Secondary Prevention of Ischemic Stroke: Updated Guidelines From AHA/ASA. Am Fam Physician. 2022. 14. Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2021. 15. Greco A, Occhipinti G, Giacoppo D, et al. Antithrombotic Therapy for Primary and Secondary Prevention of Ischemic Stroke: JACC State-of-the-Art Review. J Am Coll Cardiol. 2023. 16. Ko D, Chung MK, Evans PT, Benjamin EJ, Helm RH. Atrial Fibrillation: A Review. JAMA. 2025. 17. Michaud GF, Stevenson WG. Atrial Fibrillation. N Engl J Med. 2021. 18. David PS, Nordhues H, Vegunta S. Sex-Specific Risk Factors for Stroke in Women: Focus on the 2024 AHA/ASA Guideline. Cleve Clin J Med. 2026. 19. Pikula A, Iziduh S, Kocabas E, et al. Midlife as the Critical Window for Women's Stroke and Dementia Prevention. Stroke. 2026. 20. Poorthuis MH, Algra AM, Algra A, Kappelle LJ, Klijn CJ. Female- and Male-Specific Risk Factors for Stroke: A Systematic Review and Meta-Analysis. JAMA Neurol. 2017. 21. van Os HJA, Kanning JP, Ferrari MD, et al. Added Predictive Value of Female-Specific Factors and Psychosocial Factors for the Risk of Stroke in Women Under 50. Neurology. 2023. 22. Kernan WN, Viera AJ, Billinger SA, et al. Primary Care of Adult Patients After Stroke: A Scientific Statement From the AHA/ASA. Stroke. 2021. 23. Ebrahimi F, Ebrahimi R, Beer M, et al. Colchicine for the Secondary Prevention of Cardiovascular Events. Cochrane Database Syst Rev. 2025. 24. Ding PF, Zhang HS, Wang J, et al. Insulin Resistance in Ischemic Stroke: Mechanisms and Therapeutic Approaches. Front Endocrinol. 2023. 25. Xun P, Wu Y, He Q, He K. Fasting Insulin Concentrations and Incidence of Hypertension, Stroke, and Coronary Heart Disease: A Meta-Analysis of Prospective Cohort Studies. Am J Clin Nutr. 2013. 26. Gu T, Yang Q, Ying G, Jin B. Lack of Association Between Insulin Resistance as Estimated by Homeostasis Model Assessment and Stroke Risk: A Systematic Review and Meta-Analysis. Med Hypotheses. 2020. 27. Georgakis MK, Harshfield EL, Malik R, et al. Diabetes Mellitus, Glycemic Traits, and Cerebrovascular Disease: A Mendelian Randomization Study. Neurology. 2021. 28. Feng X, Yao Y, Wu L, et al. Triglyceride-Glucose Index and the Risk of Stroke: A Systematic Review and Dose-Response Meta-Analysis. Horm Metab Res. 2022. 29. Kernan WN, Viscoli CM, Furie KL, et al. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack (IRIS). N Engl J Med. 2016. 30. Spence JD, Viscoli CM, Inzucchi SE, et al. Pioglitazone Therapy in Patients With Stroke and Prediabetes: A Post Hoc Analysis of the IRIS Randomized Clinical Trial. JAMA Neurol. 2019. 31. Rasmussen-Torvik LJ, Yatsuya H, Selvin E, Alonso A, Folsom AR. Demographic and Cardiovascular Risk Factors Modify Association of Fasting Insulin With Incident Coronary Heart Disease and Ischemic Stroke (Atherosclerosis Risk in Communities Study). Am J Cardiol. 2010. 32. Iglesies-Grau J, Garcia-Alvarez A, Oliva B, et al. Early Insulin Resistance in Normoglycemic Low-Risk Individuals Is Associated With Subclinical Atherosclerosis. Cardiovasc Diabetol. 2023. 33. Wang T, Li M, Zeng T, et al. Association Between Insulin Resistance and Cardiovascular Disease Risk Varies According to Glucose Tolerance Status: A Nationwide Prospective Cohort Study. Diabetes Care. 2022. 34. ASCEND Study Collaborative Group, Bowman L, Mafham M, et al. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. N Engl J Med. 2018. 35. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. J Am Coll Cardiol. 2019. 36. Lip GYH, Benamouzig R, Martin AC, et al. Comparative Safety and Effectiveness of Oral Anticoagulants in Patients With Non-Valvular Atrial Fibrillation and High Risk of Gastrointestinal Bleeding: A Nationwide French Cohort Study. PLoS One. 2024. 37. Doshi SK, Kar S, Nair DG, et al. Left Atrial Appendage Closure or Anticoagulation for Atrial Fibrillation (CHAMPION-AF). N Engl J Med. 2026. 38. Ramadan A, Doma M, Ferreira Felix I, et al. Recurrent Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Left Atrial Appendage Occlusion. Pacing Clin Electrophysiol. 2026. 39. Newman CB, Preiss D, Tobert JA, et al. Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2019. 40. Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering. J Am Coll Cardiol. 2022. 41. Wang Y, Li F, Cheng Y, Gu L, Xie Z. Cardiorespiratory Fitness as a Quantitative Predictor of the Risk of Stroke: A Dose-Response Meta-Analysis. J Neurol. 2020. 42. Kurl S, Laukkanen JA, Rauramaa R, et al. Cardiorespiratory Fitness and the Risk for Stroke in Men. Arch Intern Med. 2003. 43. Ehrman JK, Keteyian SJ, Johansen MC, et al. Improved Cardiorespiratory Fitness Is Associated With Lower Incident Ischemic Stroke Risk: Henry Ford FIT Project. J Stroke Cerebrovasc Dis. 2023. 44. Prestgaard E, Mariampillai J, Engeseth K, et al. Change in Cardiorespiratory Fitness and Risk of Stroke and Death: Long-Term Follow-Up of Healthy Middle-Aged Men. Stroke. 2019. 45. Ross R, Blair SN, Arena R, et al. Importance of Assessing Cardiorespiratory Fitness in Clinical Practice: A Case for Fitness as a Clinical Vital Sign: A Scientific Statement From the American Heart Association. Circulation. 2016. 46. De Santis F, Romoli M, Foschi M, et al. Risk of Stroke With Different Levels of Leisure-Time Physical Activity: A Systematic Review and Meta-Analysis of Prospective Cohort Studies. J Neurol Neurosurg Psychiatry. 2024. 47. Nguyen NQ, Ta KT, Chuang KJ. Comparative Effects of Non-Pharmacological Interventions for Stroke Prevention in Adults: A Network Meta-Analysis. Cerebrovasc Dis. 2026. 48. Jenkins DJA, Spence JD, Giovannucci EL, et al. Supplemental Vitamins and Minerals for Cardiovascular Disease Prevention and Treatment: JACC Focus Seminar. J Am Coll Cardiol. 2021. 49. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia (REDUCE-IT). N Engl J Med. 2019. 50. Manson JE, Bassuk SS, Cook NR, et al. Vitamin D, Marine n-3 Fatty Acids, and Primary Prevention of Cardiovascular Disease: Current Evidence (VITAL). Circ Res. 2020. 51. Michos ED, Cainzos-Achirica M, Heravi AS, Appel LJ. Vitamin D, Calcium Supplements, and Implications for Cardiovascular Health: JACC Focus Seminar. J Am Coll Cardiol. 2021. 52. Adebamowo SN, Spiegelman D, Willett WC, Rexrode KM. Association Between Intakes of Magnesium, Potassium, and Calcium and Risk of Stroke: 2 Cohorts of US Women and Updated Meta-Analyses. Am J Clin Nutr. 2015. 53. Larsson SC, Traylor M, Burgess S, et al. Serum Magnesium and Calcium Levels in Relation to Ischemic Stroke: Mendelian Randomization Study. Neurology. 2019. 54. Yuan Z, Wang P, Xie Y, et al. Association of Magnesium Depletion Score With Increased Stroke Incidence and Mortality Risks in a Comprehensive Analysis. Sci Rep. 2025. 55. Tong TYN, Appleby PN, Key TJ, et al. The Associations of Major Foods and Fibre With Risks of Ischaemic and Haemorrhagic Stroke: A Prospective Study of 418,329 Participants in the EPIC Cohort. Eur Heart J. 2020. 56. Monteiro CA, Louzada ML, Steele-Martinez E, et al. Ultra-Processed Foods and Human Health: The Main Thesis and the Evidence. Lancet. 2025. 57. Bhave VM, Oladele CR, Ament Z, et al. Associations Between Ultra-Processed Food Consumption and Adverse Brain Health Outcomes. Neurology. 2024. 58. Judd SE, Gutiérrez OM, Newby PK, et al. Dietary Patterns Are Associated With Incident Stroke and Contribute to Excess Risk of Stroke in Black Americans (REGARDS). Stroke. 2013. 59. Navale SS, Mulugeta A, Zhou A, Llewellyn DJ, Hyppönen E. Vitamin D and Brain Health: An Observational and Mendelian Randomization Study. Am J Clin Nutr. 2022. 60. Harris WS. The Omega-3 Index as a Risk Factor for Coronary Heart Disease. Am J Clin Nutr. 2008. 61. Harris WS, Del Gobbo L, Tintle NL. The Omega-3 Index and Relative Risk for Coronary Heart Disease Mortality: Estimation From 10 Cohort Studies. Atherosclerosis. 2017. 62. Harris WS, Tintle NL, Etherton MR, Vasan RS. Erythrocyte Long-Chain Omega-3 Fatty Acid Levels Are Inversely Associated With Mortality and With Incident Cardiovascular Disease: The Framingham Heart Study. J Clin Lipidol. 2017. 63. Franco WG, O'Keefe EL, O'Keefe JH, et al. Omega-3 Index Improves Upon the Pooled Cohort Equation in Predicting Risk for CVD. J Clin Lipidol. 2024. 64. O'Keefe JH, Tintle NL, Harris WS, et al. Omega-3 Blood Levels and Stroke Risk: A Pooled and Harmonized Analysis of 183,291 Participants From 29 Prospective Studies. Stroke. 2024. 65. Abdelhamid AS, Brown TJ, Brainard JS, et al. Omega-3 Fatty Acids for the Primary and Secondary Prevention of Cardiovascular Disease. Cochrane Database Syst Rev. 2020. 66. Gencer B, Djousse L, Al-Ramady OT, Cook NR, Manson JE, Albert CM. Effect of Long-Term Marine ω-3 Fatty Acids Supplementation on the Risk of Atrial Fibrillation in Randomized Controlled Trials: A Meta-Analysis. Circulation. 2021. 67. Argeros Z, Xu X, Bhandari B, et al. Magnesium Supplementation and Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Hypertension. 2025. 68. Cunha AR, D'El-Rei J, Medeiros F, et al. Oral Magnesium Supplementation Improves Endothelial Function and Attenuates Subclinical Atherosclerosis in Thiazide-Treated Hypertensive Women. J Hypertens. 2017. 69. Saver JL, Starkman S, Eckstein M, et al. Prehospital Use of Magnesium Sulfate as Neuroprotection in Acute Stroke (FAST-MAG). N Engl J Med. 2015. 70. Pandey A, Patel MR, Willis B, et al. Association Between Midlife Cardiorespiratory Fitness and Risk of Stroke: The Cooper Center Longitudinal Study. Stroke. 2016. 71. Feldman DI, Al-Mallah MH, Keteyian SJ, et al. No Evidence of an Upper Threshold for Mortality Benefit at High Levels of Cardiorespiratory Fitness. J Am Coll Cardiol. 2015. 72. Billinger SA, Arena R, Bernhardt J, et al. Physical Activity and Exercise Recommendations for Stroke Survivors: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2014. 73. Ahmed S, Bogiatzi C, Hackam DG, et al. Vitamin B Deficiency and Hyperhomocysteinaemia in Outpatients With Stroke or Transient Ischaemic Attack: A Cohort Study at an Academic Medical Centre. BMJ Open. 2019.

Medical Disclaimer

This article is for educational purposes only and is not medical advice for any individual. Stroke prevention is highly individual, and the right strategy depends on your specific risk factors, medication tolerances, and goals. Always discuss new medications, dose changes, or screening decisions with your physician.